Evidence map›Paper›PMID 36065941›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2022

Development of novel 9-

Jichao Chen, Yiping Duan, Xiaoxuan Yu, Jiarou Zhong, Jing Bai, Nian-Guang Li, Zheying Zhu, Jinyi Xu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Jichao ChenSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Yiping DuanState Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, China.
Xiaoxuan YuSchool of Medicine, Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Jiarou ZhongSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Jing BaiSchool of Chemistry and Life Sciences, Suzhou University of Science and Technology, Suzhou, China.
Nian-Guang LiSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Zheying ZhuDivision of Molecular Therapeutics & Formulation, School of Pharmacy, The University of Nottingham, University Park Campus, Nottingham, UK.ORCID 0000-0002-2135-3812
Jinyi XuState Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, China.ORCID 0000-0002-1961-0402
Nanjing University of Chinese Medicine · CNChina Pharmaceutical University · CNSuzhou University of Science and Technology · CNUniversity of Nottingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of novel 9-

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsAnimalsCell Cycle CheckpointsCell Line, TumorHumansMiceAntineoplastic AgentsberberineHepatocellular carcinomalipid-water partition coefficientmitochondrial dysfunctionnatural product

Identifiers

PMID36065941
PMCPMC9467586
OpenAlexW4294719503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.